Open Access
Table 1
Extracorporeal techniques details.
| Hybrid System Components: The Hybrid System employed in the study was manufactured by Spectrum Medical and featured advanced components aimed at improving patient outcomes (Figure 1). Key components included: | •Hybrid Venous Reservoir: Includes a dual chamber for efficient blood suction management and a collapsible soft bag to minimize blood contact with foreign materials and reduce air exposure (Figure 2). |
| •Oxygenator: Spectrum Medical VT200, providing efficient oxygenation throughout the surgical procedure. | •Heat Exchanger: Quantum Standard Heat Exchanger High Flow 3/8, ensuring precise thermal control. |
| •Circuit Management: Filled with 1000 mL crystalloid solution and administered with 300 IU/kg of sodium heparin to achieve an activated clotting time of 480’’ s prior to CPB. | •Myocardial Protection: Utilized del Nido solution cardioplegia, administered every 90 minutes via a closed circuit with heat exchanger ensuring myocardial protection throughout the procedure. |
| •Perfusion System: Quantum perfusion system, delivering reliable blood flow with online continuous blood measurement via VIPER (Perfusion Record). | •Ventilation Module: Quantum ventilation module, supporting optimal gas blending and management of atmospheric and hypobaric ventilation. |
| MiECC Components: The MiECC system employed a closed type III circuit using the Stöckert S5 heart-lung machine (LivaNova, London, UK) (Figure 3). Key components included: | |
| •Venous-Arterial Line: Diameter 3/8, integrated with a venous bubble-trap (LivaNova, London, UK). | •Centrifugal Pump: Revolution Pump (LivaNova, London, UK). |
| •Oxygenator: Polypropylene fiber oxygenator (Ispire 6 F, LivaNova, London, UK) with Biopassive Coating Phisio (LivaNova, London, UK). | •Bubble Detection System: Used to remove air from the bubble trap and the circuit (Stöckert, LivaNova). |
| •Circuit Management: Filled with 1000 mL crystalloid solution and administered with 300 IU/kg of sodium heparin to achieve an activated clotting time of 480’’ s prior to CPB. | •Myocardial Protection: Utilized del Nido solution cardioplegia, administered every 90 minutes via a closed circuit with heat exchanger ensuring myocardial protection throughout the procedure. |
| •Monitoring: DO2 management monitoring was used during CPB, alongside arterial blood gas analysis using alpha-stat management at 37 °C. |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.